[1]皮青文.恩替卡韦抗病毒治疗对慢性乙肝肝硬化患者肝功能及肝硬化程度的影响[J].医学信息官方网站,2022,35(15):121-124.[doi:10.3969/j.issn.1006-1959.2022.15.028]
 PI Qing-wen.Effect of Entecavir Antiviral Therapy on Liver Function and Degree of Liver Cirrhosis in Patients with Chronic Hepatitis B Cirrhosis[J].Medical Information,2022,35(15):121-124.[doi:10.3969/j.issn.1006-1959.2022.15.028]
点击复制

恩替卡韦抗病毒治疗对慢性乙肝肝硬化患者肝功能及肝硬化程度的影响()
分享到:

《医学信息》官方网站[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年15期
页码:
121-124
栏目:
论著
出版日期:
2022-08-01

文章信息/Info

Title:
Effect of Entecavir Antiviral Therapy on Liver Function and Degree of Liver Cirrhosis in Patients with Chronic Hepatitis B Cirrhosis
文章编号:
1006-1959(2022)15-0121-04
作者:
皮青文
(新干县人民医院感染科,江西 新干 331300)
Author(s):
PI Qing-wen
(Department of Infection,Xingan County People’s Hospital,Xingan 331300,Jiangxi,China)
关键词:
慢性乙肝肝硬化肝功能肝纤维化恩替卡韦炎症反应
Keywords:
Chronic hepatitis B cirrhosisLiver functionLiver fibrosisEntecavirInflammatory response
分类号:
R512.62
DOI:
10.3969/j.issn.1006-1959.2022.15.028
文献标志码:
A
摘要:
目的 研究恩替卡韦抗病毒治疗对慢性乙肝肝硬化患者肝功能及肝硬化程度的影响。方法 选取2018年6月-2021年5月新干县人民医院收治的60例慢性乙肝肝硬化患者为研究对象,采用随机数字表法分为对照组与观察组,各30例。对照组给予阿德福韦酯抗病毒治疗,观察组给予恩替卡韦抗病毒治疗,比较两组乙肝病毒基因(HBV-DNA)、肝功能指标[总胆红素(TBL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)]、肝硬化指标(肝纤维化无创诊断指数APRI与FIB-4)、综合疗效、病毒应答情况及不良反应发生情况。结果 两组治疗后1、3个月HBV-DNA水平低于治疗前,且观察组低于对照组(P<0.05);两组治疗后TBiL、ALT、AST水平低于治疗前,且观察组低于对照组(P<0.05);两组治疗后APRI、FIB-4低于治疗前,且观察组低于对照组(P<0.05);观察组治疗有效率为93.33%,高于对照组的80.00%(P<0.05);观察组病毒应答率为90.00%,高于对照组的70.00%(P<0.05);观察组不良反应发生率为13.33%,低于对照组的30.00%(P<0.05)。结论 恩替卡韦具有积极的抗乙肝病毒作用,可改善慢性乙型肝炎肝硬化患者肝功能及肝硬化程度,提高其病毒应答反应,疗效确切,安全可行。
Abstract:
Objective To study the effect of entecavir antiviral therapy on liver function and degree of liver cirrhosis in patients with chronic hepatitis B cirrhosis.Methods A total of 60 patients with chronic hepatitis B cirrhosis admitted to Xingan County People’s Hospital from June 2018 to May 2021 were selected as the study subjects. They were divided into control group and observation group by random number table method, with 30 cases in each group. The control group was given adefovir dipivoxil antiviral therapy, and the observation group was given entecavir antiviral therapy. The hepatitis B virus gene (HBV-DNA), liver function indexes [total bilirubin (TBiL), alanine aminotransferase (ALT), aspartate aminotransferase (AST)], liver cirrhosis indexes (liver fibrosis noninvasive diagnostic index APRI and FIB-4), comprehensive curative effect, virus response and adverse reactions were compared between the two groups.Results The levels of HBV-DNA in the two groups at 1 and 3 months after treatment were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). The levels of TBL, ALT and AST in the two groups after treatment were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). APRI and FIB-4 in the two groups after treatment were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The effective rate of the observation group was 93.33%, which was higher than 80.00% of the control group (P<0.05). The virus response rate of the observation group was 90.00%, which was higher than 70.00% of the control group (P<0.05). The incidence of adverse reactions in the observation group was 13.33%, which was lower than 30.00% in the control group (P<0.05).Conclusion Entecavir has a positive anti-hepatitis B virus effect, which can promote the improvement of liver function and cirrhosis of patients with chronic hepatitis B cirrhosis, and improve their viral response. The effect is significant, safe and feasible.

参考文献/References:

[1]张绍斌,杨超.恩替卡韦治疗失代偿期慢性乙型病毒性肝炎肝硬化的临床研究[J].实用临床医药杂志,2016,20(5):57-59,63.[2]Guo HM,Liu M,Xiang YT,et al.Insomnia in Adults With Chronic Hepatitis B,Liver Failure,and Cirrhosis:A Case-Control Study[J].Perspect Psychiatr Care,2017,53(1):67-72.[3]陈岚,张蓉.恩替卡韦单药替代拉米夫定与阿德福韦酯对乙肝肝硬化患者肾脏的影响研究[J].重庆医学,2020,49(15):2533-2537.[4]杨春梅,施翠芬.恩替卡韦、富马酸替诺福韦酯治疗初治慢性乙型肝炎及代偿期肝硬化效果比较[J].临床合理用药杂志,2020,13(5):59-61.[5]范丽,张婷.拉米夫定、阿德福韦酯、恩替卡韦治疗失代偿期乙型肝炎肝硬化临床研究[J].陕西医学杂志,2019,48(7):939-941.[6]沈伟,陈彬,范久波,等.恩替卡韦和替诺福韦酯治疗乙型肝炎肝硬化的实验室及超声指标比较[J].现代仪器与医疗,2019,25(1):49-53.[7]曹艳平,隋洪婷,潘猛,等.恩替卡韦联合聚乙二醇干扰素或胸腺素治疗代偿期乙型肝炎肝硬化2年疗效随访[J].实用肝脏病杂志,2019,22(1):93-96.[8]朱凤云,蒋明光,涂玲玲,等.恩替卡韦与阿德福韦酯治疗乙肝肝硬化患者的疗效及预后比较[J].安徽医学,2018,39(11):1314-1317.[9]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J].中国肝脏病杂志(电子版),2015(3):1-18.[10]Zhang Z,Li J,Wang P,et al.Nomogram for cirrhosis in patients with chronic hepatitis B:A simple self-assessed scale for individual risk of cirrhosis[J].Sci Rep,2017,7(1):17493.[11]沈男男,王佳良,劳国琴,等.恩替卡韦和阿德福韦酯治疗乙型病毒性肝炎相关肝硬化的临床研究[J].中国临床药理学杂志,2018,34(10):1136-1139.[12]袁刚,胡爱荣,胡耀仁,等.恩替卡韦和阿德福韦酯治疗代偿期乙肝肝硬化临床疗效及远期预后[J].中国临床药理学与治疗学,2018,23(2):170-174.[13]胡大山.恩替卡韦分散片与阿德福韦治疗乙型肝炎肝硬化疗效比较[J].肝脏,2018,23(2):179-181.[14]Han Y,Zeng A,Liao H,et al.The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis[J].Int Immunopharmacol,2017,42:168-175.[15]肖玉柱.阿德福韦酯联合恩替卡韦治疗老年失代偿期乙型肝炎相关肝硬化患者疗效及血清细胞因子水平变化[J].实用肝脏病杂志,2017,20(5):546-549.[16]严瑾.恩替卡韦治疗乙型肝炎后肝硬化患者对血清炎性因子的影响[J].现代消化及介入诊疗,2017,22(1):24-26.[17]赵子龙,康海燕,张志,等.阿德福韦酯联合拉米夫定与恩替卡韦单药治疗乙肝肝硬化疗效比较[J].现代中西医结合杂志,2016,25(33):3716-3718.[18]雷子庆,张鑫.替诺福韦和恩替卡韦治疗乙型肝炎肝硬化的疗效对比[J].分子影像学杂志,2016,39(4):383-386.[19]殷燕,李捷壮,聂尚燕.恩替卡韦与阿德福韦酯治疗乙型病毒性肝炎失代偿性肝硬化患者的临床研究[J].中国临床药理学杂志,2016,32(18):1639-1642.[20]申恩华,王茉莉,王立红,等.恩替卡韦和富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎及乙型肝炎肝硬化抗病毒效果[J].中国医药导报,2018,15(28):70-73.[21]何峰,王慧,刘超.恩替卡韦对乙肝肝硬化代偿期乙肝病毒应答、肝功能水平的影响[J].海南医学,2016,27(13):2121-2123.[22]聂振汪,李荣宽.恩替卡韦对失代偿期乙型肝炎肝硬化患者肝功能及血清病毒学指标的影响[J].成都医学院学报,2016,11(3):317-320.[23]刘小莹,郑宏波,王山军,等.恩替卡韦单药方案维持对初始行拉米夫定+阿德福韦酯方案治疗慢性乙型肝炎及慢性乙型肝炎后肝硬化疗效影响[J].陕西医学杂志,2020,49(4):502-505.[24]张美平,李秀芬,邬宇美.恩替卡韦和替诺福韦治疗乙型肝炎肝硬化疗效对比[J].黑龙江医药,2018,31(1):60-62.[25]Chen Y,Cai G,Zhang C,et al.The association of serum markers of fibrosis and development of liver cirrhosis in chronic hepatitis B patients:A systematic review and meta-analysis[J].Cogent Medicine,2019,6(1):109-112.[26]陈娟娟,张瑞,陈保站,等.恩替卡韦治疗对乙肝肝硬化患者肝功能及肝硬化指标的影响[J].中国医院药学杂志,2018,38(14):1526-1529,1557.

相似文献/References:

[1]解春军.损伤性胆管狭窄手术时机对肝功能变化影响的实验研究[J].医学信息官方网站,2018,31(03):78.[doi:10.3969/j.issn.1006-1959.2018.03.024]
 XIE Chun-jun.Experimental Study on the Influence of Timing of Operation on the Changes of Hepatic Function in Patients with Traumatic Biliary Stricture[J].Medical Information,2018,31(15):78.[doi:10.3969/j.issn.1006-1959.2018.03.024]
[2]张 黎.中晚期原发性肝癌介入治疗的临床效果及对 肝功能的影响[J].医学信息官方网站,2018,31(09):20.[doi:10.3969/j.issn.1006-1959.2018.09.006]
 ZHANG Li.The Clinical Effect of Interventional Treatment of Primary Liver Cancer in Middle and Late Stage and its Effect on Liver Function[J].Medical Information,2018,31(15):20.[doi:10.3969/j.issn.1006-1959.2018.09.006]
[3]刘钰书.茵陈蒿汤辅助治疗热重于湿型病毒性肝炎患者的效果研究[J].医学信息官方网站,2018,31(14):156.[doi:10.3969/j.issn.1006-1959.2018.14.048]
 LIU Yu-shu.Effect of Yinchenhao Decoction on the Treatment of Patients with Heat Heavier than Wet Type Viral Hepatitis[J].Medical Information,2018,31(15):156.[doi:10.3969/j.issn.1006-1959.2018.14.048]
[4]潘 文,屈 阳,米 俊,等.蜂毒清1号对轻中度毒蜂蜇伤患者心肝肾功能影响的临床研究[J].医学信息官方网站,2019,32(06):151.[doi:10.3969/j.issn.1006-1959.2019.06.048]
 PAN Wen,QU Yang,MI Jun,et al.Clinical Study on the Effect of Fengduqing No.1 on Heart,Liver and Kidney Function of Patients with Mild to Moderate Poison Bee Sting[J].Medical Information,2019,32(15):151.[doi:10.3969/j.issn.1006-1959.2019.06.048]
[5]周 煜.恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的影响[J].医学信息官方网站,2019,32(22):132.[doi:10.3969/j.issn.1006-1959.2019.22.044]
 ZHOU Yu.Effect of Entecavir Combined with Microecological Preparation on Liver Function and Prognosis in Patients with Hepatitis B Cirrhosis[J].Medical Information,2019,32(15):132.[doi:10.3969/j.issn.1006-1959.2019.22.044]
[6]黄士昌.标本温度、存储时间对肝功能生化检验结果的影响[J].医学信息官方网站,2019,32(22):172.[doi:10.3969/j.issn.1006-1959.2019.22.061]
 HUANG Shi-chang.Effect of Specimen Temperature and Storage Time on Biochemical Test Results of Liver Function[J].Medical Information,2019,32(15):172.[doi:10.3969/j.issn.1006-1959.2019.22.061]
[7]王 晶.垂体后叶素联合硝酸甘油治疗肝硬化上消化道出血的效果[J].医学信息官方网站,2020,33(19):147.[doi:10.3969/j.issn.1006-1959.2020.19.046]
 WANG Jing.Effect of Pituitrin and Nitroglycerin on Upper Gastrointestinal Bleeding in Cirrhosis[J].Medical Information,2020,33(15):147.[doi:10.3969/j.issn.1006-1959.2020.19.046]
[8]毛 锋.标本溶血对生化检验中电解质、心肌酶、肝功能、血脂水平的影响[J].医学信息官方网站,2020,33(19):173.[doi:10.3969/j.issn.1006-1959.2020.19.056]
 MAO Feng.The Effect of Specimen Hemolysis on Electrolytes,Myocardial Enzymes, Liver Functionand Blood Lipid Levels in Biochemical Tests[J].Medical Information,2020,33(15):173.[doi:10.3969/j.issn.1006-1959.2020.19.056]
[9]罗志江,彭 涛,肖剑波,等.ALBI分级评估肝功能的研究进展[J].医学信息官方网站,2021,34(08):45.[doi:10.3969/j.issn.1006-1959.2021.08.012]
 LUO Zhi-jiang,PENG Tao,XIAO Jian-bo,et al.Research Progress of ALBI Grade Assessment of Liver Function[J].Medical Information,2021,34(15):45.[doi:10.3969/j.issn.1006-1959.2021.08.012]
[10]郭俊龙,曹海鹰.早期肠内营养对肝移植患者术后肝功能恢复的影响[J].医学信息官方网站,2021,34(10):140.[doi:10.3969/j.issn.1006-1959.2021.10.040]
 GUO Jun-long,CAO Hai-ying.The Effect of Early Enteral Nutrition on the Recovery of Liver Function After Liver Transplantation[J].Medical Information,2021,34(15):140.[doi:10.3969/j.issn.1006-1959.2021.10.040]

更新日期/Last Update: 1900-01-01